Nanotechnology based drug delivery systems are already in clinical use and many more have recently advanced into clinical trials.Advances in much needed targeted therapies with biocompatible, multifunctional nanomaterials are already producing excellent preclinical results with desirable safety and efficacy profiles.While such advances are promising and encouraging, rigorous investigations and data reproducibility with new research formulations are critical for clinical translation.